Gland Pharma Limited (BOM:543245)

Market Cap	308.34B
Revenue (ttm)	57.20B
Net Income (ttm)	7.70B
Shares Out	n/a
EPS (ttm)	46.75
PE Ratio	40.03
Forward PE	29.50
Dividend	18.00 (0.95%)
Ex-Dividend Date	Aug 14, 2025

Volume	9,392
Average Volume	8,771
Open	1,925.35
Previous Close	1,928.25
Day's Range	1,876.00 - 1,929.00
52-Week Range	1,200.00 - 2,130.00
Beta	n/a
RSI	36.78
Earnings Date	Aug 1, 2025

About Gland Pharma

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neopla...

• Industry: Pharmaceutical Preparations
• Founded: 1978
• Employees: 4,351
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543245

Financial Performance

In 2024, Gland Pharma's revenue was 56.17 billion, a decrease of -0.85% compared to the previous year's 56.65 billion. Earnings were 6.99 billion, a decrease of -9.57%.